Celeheal 100 (Celecoxib)

Uses

Celeheal 100 (Celecoxib) is an anti-inflammatory drug (specifically a COX-2 inhibitor) that is used to treat rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriatic arthritis. Celeheal 100 (Celecoxib) has anti-inflammatory, antipyretic, analgesic effect.

Celecoxib selectively inhibits COX-2 and blocks the formation of pro-inflammatory PG. At therapeutic concentrations, Celecoxib does not inhibit COX-1.

In clinical trials in healthy volunteers, celecoxib in single doses up to 800 mg and 600 mg twice a day for 7 days (higher than the recommended therapeutic doses) did not reduce platelet aggregation and did not increase bleeding time. Suppression of the synthesis of PGE2 can lead to fluid retention due to increased reabsorption in the thick ascending segment of the loop of Henle and, possibly, other distal areas of the nephron. PGE2 inhibits the reabsorption of water in the collecting tubules, interfering with the action of antidiuretic hormone.

Celeheal (Celecoxib) Dosage and Administration

Always follow your doctor`s instructions when using Celeheal 100 (Celecoxib) to get the safest and most effective results from treatment. Celeheal 100 (Celecoxib) should be swallowed whole with a full glass of water.

It is necessary to apply a minimum effective dose with the least possible duration of treatment.

At osteoarthritis it is recommended to take 100 mg 2 times a day or 200 mg once a day.

In rheumatoid arthritis, the initial dose is 100 mg 2 times a day. If necessary, the dose can be increased to 200 mg 2 times a day.

The maximum daily dose is 400 mg.

Celeheal (Celecoxib) Side effects

The use of Celeheal 100 (Celecoxib) may cause side effects in some patients including:

• stomach ache
• diarrhea
• constipation
• dyspepsia
• flatulence
• peripheral edema
• dizziness
• weakness
• dermatitis
• rash, itching

Contact your doctor immediately if you experience any serious or worrying symptoms.

Celeheal (Celecoxib) Precautions

Pregnancy: Adequate and strictly controlled studies in pregnant women have not been conducted. In pregnancy, it is possible if the expected effect of therapy outweighs the potential risk to the fetus.

Breastfeeding: Celecoxib is excreted in the milk of lactating rats, while the concentrations in milk are similar to those in the plasma. It is unknown whether celecoxib penetrates women's breast milk, so breastfeeding should be discontinued during treatment or avoided during breastfeeding.